Table: diabetes_ndcs_wac_increases_5_year_history , manufacturer_name like B*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

year_str	oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014030	TRADJENTA 5 MG TABLET	01/01/2019	24.69	436.17	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=228	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014061	TRADJENTA 5 MG TABLET	01/01/2019	82.30	1453.90	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=229	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014090	TRADJENTA 5 MG TABLET	01/01/2019	74.07	1308.51	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=230	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014618	JENTADUETO 2.5 MG-500 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=169	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014660	JENTADUETO 2.5 MG-500 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=170	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014718	JENTADUETO 2.5 MG-850 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=171	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014760	JENTADUETO 2.5 MG-850 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=172	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014818	JENTADUETO 2.5 MG-1,000 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=173	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014860	JENTADUETO 2.5 MG-1,000 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=174	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015230	JARDIANCE 10 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=163	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015237	JARDIANCE 10 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=164	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015290	JARDIANCE 10 MG TABLET	01/01/2019	83.69	1478.54	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=165	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015330	JARDIANCE 25 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=166	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015337	JARDIANCE 25 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=167	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015390	JARDIANCE 25 MG TABLET	01/01/2019	83.69	1478.54	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=168	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015918	SYNJARDY 5-500 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=220	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015960	SYNJARDY 5-500 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=221	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597016818	SYNJARDY 12.5-1,000 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=222	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597016860	SYNJARDY 12.5-1,000 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=223	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597017518	SYNJARDY 5-1,000 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=224	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597017560	SYNJARDY 5-1,000 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=225	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597018018	SYNJARDY 12.5-500 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=226	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597018060	SYNJARDY 12.5-500 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=227	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597027073	JENTADUETO XR 2.5 MG-1,000 MG	01/01/2019	24.69	436.17	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=175	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597027094	JENTADUETO XR 2.5 MG-1,000 MG	01/01/2019	74.07	1308.51	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=176	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597027533	JENTADUETO XR 5 MG-1,000 MG TB	01/01/2019	24.69	436.17	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=177	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597027581	JENTADUETO XR 5 MG-1,000 MG TB	01/01/2019	74.07	1308.51	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=178	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014030	TRADJENTA 5 MG TABLET 30	01/01/2020	26.17	462.34	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=369	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014061	TRADJENTA 5 MG TABLET 100	01/01/2020	87.23	1541.13	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=370	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014090	TRADJENTA 5 MG TABLET 90	01/01/2020	78.51	1387.02	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=371	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014618	JENTADUETO 2.5 MG-500 MG 180	01/01/2020	78.51	1387.02	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=373	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014660	JENTADUETO 2.5 MG-500 MG 60	01/01/2020	26.17	462.34	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=374	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014718	JENTADUETO 2.5 MG-850 MG 180	01/01/2020	78.51	1387.02	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=375	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014760	JENTADUETO 2.5 MG-850 MG 60	01/01/2020	26.17	462.34	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=376	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014818	JENTADUETO 2.5 MG-1,000 MG 180	01/01/2020	78.51	1387.02	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=377	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014860	JENTADUETO 2.5 MG-1,000 MG 60	01/01/2020	26.17	462.34	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=378	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015230	JARDIANCE 10 MG TABLET 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=379	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015237	JARDIANCE 10 MG 30 TABLET	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=380	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015290	JARDIANCE 10 MG TABLET 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=381	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015330	JARDIANCE 25 MG TABLET 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=382	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015337	JARDIANCE 25 MG 30 TABLET	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=383	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015390	JARDIANCE 25 MG TABLET 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=384	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015918	SYNJARDY 5-500 MG TABLET 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=386	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015960	SYNJARDY 5-500 MG TABLET 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=387	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597016818	SYNJARDY 12.5-1,000 MG 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=389	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597016860	SYNJARDY 12.5-1,000 MG 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=390	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597017518	SYNJARDY 5-1,000 MG 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=391	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597017560	SYNJARDY 5-1,000 MG 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=392	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597018018	SYNJARDY 12.5-500 MG 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=393	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597018060	SYNJARDY 12.5-500 MG 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=394	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597027073	JENTADUETO XR 2.5 MG-1,000 MG 60	01/01/2020	26.17	462.34	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=396	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597027094	JENTADUETO XR 2.5 MG-1,000 MG 180	01/01/2020	78.51	1387.02	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=397	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597027533	JENTADUETO XR 5 MG-1,000 MG TB 30	01/01/2020	26.17	462.34	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=398	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597027581	JENTADUETO XR 5 MG-1,000 MG TB 90	01/01/2020	78.51	1387.02	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=399	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597028073	SYNJARDY XR 10 mg-1,000 mg 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=400	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597028090	SYNJARDY XR 10 mg-1,000 mg 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=401	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597029059	SYNJARDY XR 5 mg-1,000 mg 180	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=406	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597029074	SYNJARDY XR 5 mg-1,000 mg 60	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=407	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597029578	SYNJARDY XR 25 mg-1,000 mg 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=408	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597029588	SYNJARDY XR 25 mg-1,000 mg 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=409	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597030045	SYNJARDY XR 12.5 mg-1,000 mg 60	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=410	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597030093	SYNJARDY XR 12.5 mg-1,000 mg 180	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=411	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.